Cost Management Insights: SG&A Expenses for Zoetis Inc. and ADMA Biologics, Inc.

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the dynamic world of biopharmaceuticals, effective cost management is crucial. Over the past decade, Zoetis Inc. and ADMA Biologics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Zoetis Inc. consistently maintained a robust SG&A expense, peaking at approximately $2.15 billion in 2023, reflecting a steady growth of around 31% from 2014. In contrast, ADMA Biologics, Inc. exhibited a more aggressive increase, with SG&A expenses surging by over 1,100% during the same period, reaching nearly $59 million in 2023. This stark difference highlights Zoetis's stable expansion strategy compared to ADMA's rapid scaling efforts. As the biopharma landscape evolves, these insights into cost management strategies offer valuable lessons for industry stakeholders.